LuciBriga (Brigatinib) 180 mg
LuciBriga 180 (Brigatinib 180 mg) is a next-generation Tyrosine Kinase Inhibitor (TKI) designed for specific types of lung cancer.
Manufacturer: Lucius Pharmaceuticals. A generic equivalent to Alunbrig.
The "Brain Penetration" Advantage:
One of the biggest challenges in treating ALK-positive cancer is brain metastasis. LuciBriga is engineered to cross the blood-brain barrier effectively, targeting tumors in the brain that older drugs (like Crizotinib) often miss.
✅ Key Benefit: Superior efficacy in patients with CNS (Central Nervous System) progression.
Indicated for the treatment of adult patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC):
- First-line treatment: For newly diagnosed patients.
- Second-line treatment: For patients whose disease has progressed on or who are intolerant to Crizotinib.
Dosage Form: 180 mg Tablet.
⚠️ CRITICAL DOSING STEP-UP:
Do not start directly with 180 mg.
- Lead-in Period (Days 1-7): Start with 90 mg once daily to reduce the risk of pulmonary side effects.
- Maintenance (Day 8+): If tolerated, increase to the standard dose of 180 mg once daily.
💊 Administration: Take once daily with or without food. Swallow the tablet whole.
- Hypersensitivity to Brigatinib.
- Pregnancy and breastfeeding (embryo-fetal toxicity).
- Severe hepatic impairment (caution required).
Regular monitoring is required for:
- Respiratory Symptoms: Cough or dyspnea (signs of pneumonitis/ILD), typically early in treatment.
- Hypertension: High blood pressure.
- Bradycardia: Slow heart rate.
- Hyperglycemia: Elevated blood sugar levels.
What Customers Say
No reviews yet
Your review can be the first!